Nothing beats SOHO in Houston in September
Register today at soho.click/2025. Become a member at soho.click/join.
SOHO 2025
Meeting News
Society Updates
Cellular Therapy
Lymphoma
Indolent B-Cell Lymphomas
News
FDA grants priority review for liso-cel in relapsed or refractory MZL
The US Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for lisocabtagene maraleucel (liso-cel; Breyanzi) for adults with
Society Updates
Virtual SOHO Breakthroughs in Blood Cancers meeting launches November 20
The new meeting offers an accessible format that meets the needs of busy hematologic oncologists, bringing the best in patient care knowledge directly
News
EC approves obe-cel for relapsed or refractory B-ALL
The European Commission (EC) has granted marketing authorization to the chimeric antigen receptor T-cell therapy obecabtagene autoleucel (obe-cel; AUCATZYL) for adults ages 26
Lymphoma
Indolent B-Cell Lymphomas
EMA grants PRIME designation to Waldenstrom’s macroglobulinemia therapy BGB-16673
The European Medicines Agency (EMA) has granted (PRIority MEdicines) designation to the investigational Bruton’s tyrosine kinase (BTK) degrader, BGB-16673, for the treatment of
Acute Myeloid Leukemia
Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory AML
A study assessed CPX-531 plus venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) and found that the combination was particularly
Multiple Myeloma
News
Triplet therapy maintains, improves quality of life in relapsed/refractory myeloma
The combination of belantamab mafodotin, bortezomib, and dexamethasone generally maintained or improved health-related quality of life (HRQOL) in patients with relapsed or refractory
Cellular Therapy
News
Study backs liso-cel as second-line treatment in transplant-ineligible LBCL
The final analysis from the phase 2 PILOT study showed that after a median of 18.2 months, response to lisocabtagene maraleucel (liso-cel) was
Multiple Myeloma
Isatuximab approved in the EU for the treatment of transplant-eligible MM
The European Commission has approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the induction treatment of adult patients with newly
Acute Myeloid Leukemia
Myelodysplastic Syndromes
News
Combo eprenetapopt plus azacitidine is well-tolerated in TP53-mutated MDS and AML
A phase 2 study found that eprenetapopt plus azacitidine induced responses in patients with TP53-mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This